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Abstract
Background: HAART has improved the survival of HIV infected patients. However, compared to
patients in high-income countries, patients in resource-poor countries have higher mortality rates.
Our objective was to identify independent risk factors for death in Ethiopian patients treated with
HAART.
Methods: In a district hospital in Ethiopia, we treated adult HIV infected patients with HAART
based on clinical and total lymphocyte count (TLC) criteria. We measured body weight and
complete blood cell count at baseline, 4 weeks later, then repeated weight every month and
complete blood cell count every 12 weeks. Time to death was the main outcome variable. We used
the Kaplan Meier and Cox regression survival analyses to identify prognostic markers. Also, we
calculated mortality rates for the different phases of the follow-up.
Results: Out of 162 recruited, 152 treatment-naïve patients contributed 144.1 person-years of
observation (PYO). 86 (57%) of them were men and their median age was 32 years. 24 patients
died, making the overall mortality rate 16.7 per 100 PYO. The highest death rate occurred in the
first month of treatment. Compared to the first month, mortality declined by 9-fold after the 18th
week of follow-up. Being in WHO clinical stage IV and having TLC<= 750/mcL were independent
predictors of death. Haemoglobin (HGB) <= 10 g/dl and TLC<= 1200/mcL at baseline were not
associated with increased mortality. Body mass index (BMI) <= 18.5 kg/m2 at baseline was
associated with death in univariate analysis. Weight loss was seen in about a third of patients who
survived up to the fourth week, and it was associated with increased death. Decline in TLC, HGB
and BMI was associated with death in univariate analysis only.
Conclusion: The high mortality rate seen in this cohort was associated with advanced disease
stage and very low TLC at presentation. Patients should be identified and treated before they
progress to advanced stages. The underlying causes for early death in patients presenting at late
stages should be investigated.
Background
In resource-poor countries, access to antiretroviral therapy
(ART) has improved during the last years and mortality
rates among treated patients have declined substantially
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countries, patients in resource-poor countries are at higher
risk of death in the early months of treatment [3]. To
avoid such early deaths, we need to identify possible risk
factors and potential causes of death. This requires good
laboratory setup, trained personnel, and uninterrupted
supply of drugs and laboratory reagents. Unfortunately,
despite the current efforts to expand treatment in
resource-poor settings, lack of satisfactory laboratories
continues to be a challenge [4]. Even if we manage to get
the equipment to such settings, as we do now in many
urban settings in Africa, it is often difficult to find trained
personnel, the electricity supply is unreliable, and the cost
of laboratory reagents is expensive [5]. To make ART avail-
able to people living in areas with only basic laboratory
setup, we need to look for simplified ways of doing this.
Earlier studies have shown that the total lymphocyte
count (TLC), haemoglobin (HGB), body mass index
(BMI), body weight and other simple laboratory and clin-
ical markers predict mortality in HIV infected patients and
thus can be used to identify patients at risk of dying [6-
11]. However, most of these studies were done in
untreated patients. Few studies have evaluated the useful-
ness of such simple markers as predictors of clinical events
in patients receiving highly active antiretroviral therapy
(HAART) [6].
In Ethiopia, we treated and followed patients using the
WHO clinical stage and the TLC as criteria for beginning
treatment [12]. The objective of this study was to identify
predictors of early death in Ethiopian patients treated
with HAART in a setting with only basic laboratory setup.
Methods
Study setting
We did this study at Arba Minch Hospital in southern
Ethiopia. Arba Minch Hospital is a district hospital
located 500 km south of Addis Ababa. The hospital serves
about 1.5 million people with capacity of 158 beds. Since
the early 1990s, the hospital has been delivering HIV
counselling and testing services. In 2002, in preparation
to start ART, we trained staff, renovated rooms, designed
patient record forms and installed basic laboratory equip-
ment. In January 2003, we started adult HIV clinic. A med-
ical doctor, assisted by two others, headed the clinic.
Other members of the team included five nurse counsel-
lors, two laboratory technicians, two community agents,
and a data clerk. The health workers were permanent
employees of the hospital. The community agents and the
data clerk were recruited through a public notice. These
were secondary school leavers with previous record of
anti-HIV activities in the community. Familiarity with
data management and computer literacy were additional
criteria for the data clerk. All members of the team com-
pleted the necessary national courses.
We started ART in August 2003 as one of the first public
hospitals to start ART in Ethiopia. Prior to that, patients
were treated only for opportunistic infections. We previ-
ously reported the pattern of disease progression among
untreated patients [13], and the results comparing the
clinical outcome before and after treatment with HAART
[14]. Here, we report the outcome of the first consecutive
patients who were treated with HAART at our clinic
between August 2003 and January 2005 and followed
through 9 August, 2005.
Patient flow, treatment and follow-up
A nurse referred all HIV infected adult patients (age >= 15
years) to a medical doctor following a standard counsel-
ling and testing procedure [15] and after recording socio-
demographic information, body weight, height and test
results in a standardized patient record form. The doctor
did standard clinical examination and staged patients
according to the WHO clinical staging system [16].
Following clinical staging, complete blood cell count
(CBC) was measured in all patients using automated hae-
matology analyser (Sysmex Kx-21, Sysmex Corporation,
Kobe, Japan). CD4 machines were not available. In those
with indication for HAART, we did liver and renal func-
tion tests using a semi-automatic photometer (Photome-
ter 5010, Riele, version 3.0) at baseline and then regularly
according to the national treatment guideline [12].
According to the guideline, only symptomatic patients
(WHO stage II-IV) were eligible for treatment. In stage II,
the TLC<= 1200/mcL was used as an additional criterion.
Patients were treated on a first-come first-served basis. Tri-
ple combinations of stavudine (d4T), lamivudine (3TC),
nevirapine (NVP), zidovudine (ZDV), and efavirenz
(EFV) were available. d4T/3TC/NVP was the first-line
combination of choice. EFV was reserved for patients in
their intensive phase of antituberculosis therapy. Drugs
were refilled every 4 weeks. At each visit, we measured
body weight. CBC was repeated 4 weeks later and then
every 12 weeks.
We assigned unique identification numbers to each newly
started patient. The data clerk then recorded the informa-
tion and notified the community agents. Every month, the
community agents visited the patients in their homes and
reported the status of each patient to the data clerk and to
the doctor. Death was the main outcome variable, and all
non-accidental deaths were considered HIV-related. Spe-
cific causes of death were not determined. Also, the com-
munity agents reported if the patients were lost,
transferred or stopped treatment.Page 2 of 7
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lowing events, whichever occurred first: (i) if the patient
was lost to follow-up, the date of the last contact the
patient had with the community agent (ii) if the patient
was transferred to another health institution, the date of
transfer, (iii) if the patient stopped treatment, the last date
of drug re-supply plus two months, and (iv) if the patient
was alive and on treatment at the end of the follow-up,
August 9 2005.
Statistical analysis
We used the Kaplan-Meier and the Cox-regression survival
analysis techniques to identify predictors of death. We
included the baseline WHO clinical stage, TLC, BMI, and
HGB as potential predictors. TLC, BMI, and HGB were
treated as dichotomous variables at clinically useful cut-
off points as described elsewhere [13,14]. Also, we calcu-
lated the magnitude and direction of change in HGB,
body weight, BMI, and TLC values at the first and second
follow-up visits. Then we dichotomized the resulting
change in the laboratory and clinical values at two cut-off
points: (i) [no change or decrease] versus [increase]; (ii)
[decrease] versus [no change or increase]. Thus we evalu-
ated changes in HGB, body weight, BMI and TLC from
baseline to the first and second visits as potential predic-
tors of death.
In the multivariate Cox regression model, we included
only those variables significantly associated with death in
univariate analysis. We included interaction terms in mul-
tivariate models to check for multicolinearity. Results
were presented as hazard rations (HR) with 95% confi-
dence intervals (95% CI). We used the Kaplan-Meier
curves to highlight important features and the Log-rank
test was used to test for statistical significance.
We calculated mortality rates for each phase of the follow-
up: (i) from baseline to the first follow-up visit, (ii) from
baseline to the 2nd follow-up visit, (iii) from the first fol-
low-up to the second follow-up visit, (iv) from the first
follow-up visit to the end of the study, (v) from the second
follow-up visit to the end of the study, and (vi) from base-
line to the end of the study. Mortality rates were described
as number of deaths per 100 person-years of observation
(PYO). Then we calculated mortality rate ratios for each
phase of the follow-up. We used SPSS version 14.0 (SPSS
Inc., Chicago, IL, USA) for data analysis. All statistical tests
were two-sided and P <0.05 was considered statistically
significant.
Ethical considerations
The National Ethics Review Committee in Ethiopia and
the Regional Committee for Medical Research Ethics in
Western Norway approved the study protocol. All patients
gave informed consent before HIV testing and for taking
part in the study.
Results
Baseline results
We enrolled and treated 162 patients between August
2003 and January 2005. Ten treatment-experienced
patients were excluded from analysis. Out of the 152 treat-
ment-naïve patients, 86(57%) were men and 66 (43%)
were women. Their median age was 32 years [interquartile
range (IQR), 28.5–40]. 34 patients with no follow-up lab-
oratory records were included in the baseline analysis but
excluded from the follow-up analysis which included
change in specific laboratory values as predictors. In 12 of
the 34 patients, end point events including eight deaths
occurred before the planned first visit. In the remaining 22
patients, the events occurred after the planned first visit (5
died within 5–12 weeks of starting treatment, 1 stopped,
1 died after 12 weeks, 15 were still on follow-up). 68%
(104/152) of the treatment-naïve patients were in WHO
stage III, 23% (35/152) in stage IV, and 9% (13/152) in
stage II. 72 patients (47%) started d4T/3TC/NVP,
45(30%) d4T/3TC/EFV, 23 (15%) ZDV/3TC/NVP and 12
(8%) patients received ZDV/3TC/EFV. The general profile
of the cohort is shown in Figure 1.
The median (range) HGB was 9.1 g/dl (4.9–12.7); 8.5 g/
dl (4.4–13.9) for women and 9.3 g/dl (3.7–15.3) for men
(P = 0.078). 67% (102 of 152 patients) had HGB<= 10 g/
dl at presentation. The median (range) TLC count was
1000 cells/mcL (200–4800) and similar among men and
women (P = 0.966). The median (range) weight was 48 kg
(32–83)] for women and 53 kg (35–74)] for men. Their
median (range) BMI was 18.3 (13.0–27.8); 18.6 (13.5–
27.8) in women and 18.2 (13.0–24.6) in men.
Follow-up results
Change in selected clinical and laboratory values
The median time to the first follow-up visit was 4 weeks
(IQR, 4–5), and the second visit was at a median time of
18 weeks (IQR, 16–22). The median (95% range) weight
gain was 1 kg (-7.4, 7.7) and 3 kg (-8, 14.7) at the first and
second follow-up visits, respectively. The HGB declined
by a median of 0.20 g/dl (95% range;-5.97, 4.50) at week
4, while it increased by a median of 0.60 g/dl (95% range;
-6.94, 3.90) from baseline to week 18. The TLC increased
by a median (95% range) of 100 cells/mcL (-1125, 2180)
and 300 cells/mcL (-2025, 1700) at weeks 4 and 18,
respectively. When described as dichotomous changes,
34% (31/91) of the patients lost weight from baseline to
the first visit. Similarly, decline in TLC was recorded in
35% (35/101) of the patients at week 4.Page 3 of 7
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As of August 9 2005, 152 treatment naïve patients contrib-
uted 144.1 PYO. 24 patients died during a median follow-
up of 55 weeks (IQR; 29–71 weeks), making the overall
mortality rate 16.7 per 100 PYO (24 deaths/144.1 PYO).
33% (8/24) and 75% (18/24) of the deaths occurred
within 4 and 18 weeks, respectively after starting treat-
ment. Thus the mortality rates for the first 4 and 18 weeks
were 57.5 (8/13.9 PYO) and 37.3 (18/48.3) per 100 PYO,
respectively. After the 4th week, mortality declined to 12.3
per 100 PYO (16 deaths/130.2 PYO). The mortality fur-
ther declined to 6.3 per 100 PYO (6 deaths/95.8 PYO)
after the 18th week of follow-up. Table 1 describes mortal-
ity rates for different phases of the follow-up.
In univariate analysis, TLC <= 1200/mcL and HGB <= 10
g/dl at baseline were not associated with mortality (P > .1
for both). The BMI<= 18.5 kg/m2 was significantly associ-
ated with overall mortality only in univariate analysis [HR
(95%CI) = 2.9 (1.04–8.01), P = 0.042]. TLC<= 750/mcL
at baseline was the strongest predictor of overall mortality
[HR (95%CI) = 3.4 (1.5–7.6), while baseline WHO stage
IV was the strongest predictor of death in the first 4 weeks
[HR (95%CI) = 9.2 (1.8–45.8), P = 0.007]. Tables 2 and 3
summarize the Cox regression analyses.
Out of the 104 patients with at least one follow-up CBC,
9 patients died over a median period of 61 weeks from
baseline (IQR; 42–74 weeks). Weight loss at week 4 was
associated with shorter survival compared with no change
or weight gain (Log-rank; P = 0.009). Negative or no
change in the TLC at week 4 was not associated with mor-
tality (Log rank; P = 0.532), but negative or no change
from baseline to week 18 was significantly associated with
death (Log-rank; P = 0.008). Figure 2 shows the survival
estimates. Decline in BMI from baseline to the first follow-
up visit was also associated with poor prognosis (Log-
rank; P = 0.012). Patients with decline in HGB value at the
first follow-up visit had worse prognosis than those who
had no or positive change in HGB level (Log-rank; P =
0.040). In Cox regression analysis none of these variables
were associated with mortality (data not shown).
Discussion
In this cohort, mortality was highest during the first
month of treatment, about 9-fold higher compared to
mortality after the 18th week of follow-up. The WHO clin-
ical stage was the strongest predictor of death in the first
month. The TLC<= 750/mcL, but not the TLC<= 1200/
mcL, was strongly associated with overall mortality in this
cohort. A third of the patients who survived up to the
fourth week lost body weight, and weight loss was associ-
ated with increased death after the first month. Also,
decline in the TLC from baseline to the 18th week pre-
dicted death.
The findings have practical implications for managing
HIV infected patients in resource-limited settings. The
high early mortality in patients with advanced disease
implies the need for starting treatment earlier. This
requires early diagnosis of HIV infection through
improved counselling and testing practices. For patients
Table 1: Mortality rates and rate ratios by treatment phase, 
Arba Minch Hospital, 2006
Treatment phase Deaths PYO Rate Rate ratio (95%CI)
0–4 weeks 8 13.9 57.5 1
0–18 weeks 18 48.3 37.3 0.7 (0.3–1.7)
4–18 weeks 10 34.4 29.1 0.5 (0.2–1.2)
4 weeks-end of study 16 130.2 12.3 0.2 (0.1–0.5)
18 weeks-end of study 6 95.8 6.3 0.1 (0.03–0.3)
Overall 24 144.1 16.7 0.3 (0.2–0.4)
PYO = Person-Years of Observation 95%CI = 95% Confidence 
Interval
Cohort profileFigure 1
Cohort profile. 34 patients had no follow-up laboratory 
records at 4 weeks. In 12 of the 34 patients, end point events 
including eight deaths occurred before the planned first visit.Page 4 of 7
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with the patient may help prevent potentially treatable
conditions such as mycobacterial infections [17]. The
other striking finding in this study is the very low TLC
which predicted mortality. Although the recommended
TLC for initiating treatment is below 1200/mcL, this failed
to identify patients at immediate risk of dying. This high-
lights the need for paying closer attention to patients with
very low levels of TLC. Weight loss is still a common prob-
lem in patients treated with HAART, and its presence
should alert further search for underlying causes.
The pattern of mortality observed in our cohort is consist-
ent with findings from other resource-poor settings. In
Senegalese patients, mortality in the first year of follow-up
was 12.5 per 100 PYO, and decreased to 0.9 per 100 PYO
at five years [17]. The overall mortality rate of 16.7 per 100
PYO in our cohort is comparable to the Senegalese cohort
in the first year. In South Africa, Lawn et al reported a reg-
ular decline in mortality from 35.7 during pre-treatment
follow-up to 17.5 per 100 PYO during the first month of
treatment [18]. After 6–9 months, the mortality in the
South African cohort was lower by about 13-fold. In our
cohort, although the first-month mortality was much
higher at 57.5 per 100 PYO, the 9-fold decline observed
after 18 weeks of follow-up was comparable. Inclusion of
only symptomatic patients (stage II-IV) in our cohort
might have contributed to the observed difference in mor-
tality. A pooled analysis of data from low-income and
high-income countries showed that mortality was higher
in low-income countries by 4.3-fold during the first
month, but the reported mortality rate was low at 5.8% in
the first year [3]. As stated by the authors, exclusion of
substantial proportion of patients from the analysis might
have resulted in a biased estimate in their report.
A few studies have evaluated the prognostic value of the
TLC in treated patients [6,17]. In the Senegalese patients,
TLC<= 1200/mcL was associated with increased risk of
death. However, when adjusted for anaemia it did not
predict mortality [17]. In our cohort, TLC<= 750/mcL, but
not TLC<= 1200/mcL, was an independent predictor of
death. Since we treated only symptomatic patients whose
median TLC was 1000/mcL, it is likely the small number
of patients with TLC >1200/mcL affected our results.
HGB and BMI are described as important prognostic
markers either independently or in combination with the
TLC both in untreated and in treated patients [9,17,19-
22]. In our cohort, BMI<= 18.5 kg/m2 was significantly
associated with overall mortality in univariate analysis,
but not when adjusted for TLC<= 750/mcL and WHO
clinical stage. HGB<= 10 g/dl was also associated with
increased overall mortality in univariate analysis only.
This could be because of the few patients with HGB and
BMI values above the stated thresholds.
As shown by others, we found that the WHO clinical stage
was an independent marker of mortality in patients
treated with HAART [17,18]. Compared to the TLC, the
WHO stage was a stronger predictor of death in the first
month of treatment. While the ultimate goal should be to
treat patients before they progress to such advanced
stages, doctors in new settings will continue to treat such
Table 3: Hazard ratios (HR) of death in the first four weeks of treatment, Arba Minch Hospital, 2006
Factor Crude HR(95%CI) P-value Adjusted HR (95%CI) P-value
WHO stage IV vs. II-III 10.5 (2.1–52.4) 0.004 9.2 (1.8–45.8) 0.007
TLC<= 750 vs. >750/mcL 5.2 (1.2–21.9) 0.024 4.4 (1.05–18.5) 0.043
HGB<= 10 vs. >10 g/dl 3.5 (0.4–28.3) 0.244 -- --
TLC<= 1200 vs. >1200/mcL 3.4 (0.4–25.7) 0.282 -- --
BMI<= 18.5 vs. >18.5 kg/m2 1.5 (0.3–9.3) 0.629 -- --
HGB=Haemoglobin TLC=total lymphocyte count BMI=Body Mass Index WHO=World Health Organization HR=Hazard Ratio 95%CI = 95% 
Confidence Interval
Table 2: Predictors of overall survival according to Cox regression analyses, Arba Minch Hospital, 2006
Factor Crude HR (95%CI) P-value Adjusted HR (95%CI) P-value
TLC <= 750 vs. >750/mcL 3.6 (1.5–8.1) 0.002 3.6 (1.4–9.6) 0.009
WHO stage IV vs. II-III 3.7 (1.6–8.5) 0.002 2.7 (1.01–7.3) 0.047
BMI <= 18.5 vs. >18.5 kg/m2 2.9 (1.04–8.0) 0.042 2.7 (0.9–7.4) 0.062
HGB <= 10 g/dl vs. >10 g/dl 2.5 (0.8–7.4) 0.094 -- --
TLC <= 1200 vs. >1200/mcL 2.3 (0.8–6.8) 0.130 -- --
HGB = Haemoglobin TLC = total lymphocyte count BMI = Body Mass Index WHO = World Health Organization HR = Hazard Ratio 95%CI = 95% 
Confidence IntervalPage 5 of 7
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Therefore, careful documentation of the patient's disease
stage will be helpful in identifying patients who need
more intense follow-up. Improving the counselling and
testing practices should be viewed as a more sustainable
strategy.
Despite being an easily recognizable and common condi-
tion, weight loss has not been studied among resource-
poor adult patients treated with HAART. The prognostic
value of weight loss has been well documented in devel-
oped countries [24-26]. In one study, about a third of the
patients treated with HAART had weight loss, as is in our
patients, and it remained the most important prognostic
marker [24]. Poor nutritional intake, metabolic distur-
bances because of drugs, and infectious conditions such as
tuberculosis could be possible contributing reasons [27].
The main limitation of this study is the small number of
patients and events. Despite the clear trend towards
increased mortality in patients with BMI<= 18.5 kg/m2
and HGB<= 10 g/dl, we were not able to determine
whether these were independent factors. The same is true
for the TLC <= 1200/mcL. Therefore, further follow-up of
the cohort with inclusion of more patients should give
answers to these questions.
Conclusion
We found a very high mortality rate in this cohort espe-
cially during the first month of treatment. The prognosis
was worse in patients with advanced disease and with
TLC<= 750/mcL. This highlights the need for identifying
and treating patients early through improved counselling
and testing strategies. Moreover, the underlying mecha-
nisms for the weight loss observed in a third of our
patients should be investigated and, if found, interven-
tions should be planned for.
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